info@flamel.com
 
Historical Earnings
Presentations
SECFilings
Stock Quote/Chart
Request Information
Events Calendar
E-mail Alerts
Press Room
Latest News
Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Micropump® Technologies
From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info



Latest News
Latest Conference calls

Annual Reports
Annual Report 2009
Annual Report 2006 (PDF)
Annual Report 2005 (PDF)
Annual Report 2007 (PDF)
Annual Report 2008 (PDF)
Annual Report 2008 with 20-F (PDF)


Flamel Technologies Corporate Presentation - July 2010
To view the latest presentation, click here.


Financial Summary

3 months ended
June 30, 2010 ($000)
Total Revenue 7,515
Total Costs and Expenses (12,243)
Profit/(loss) from operations (4,728)
Net loss (4,290)
Cash and Marketable Securities Position $ 33.7 MM
Diluted EPS ($ 0.18)
Basic shares outstanding 24.41 MM

Contact
Charles Marlio
Director of Strategic Planning and Investor Relations

33 avenue du Dr. Georges Levy
69693 Venissieux Cedex
France
Phone: (+33) 472-783-423
marlio@flamel.com

Frederick Simonin
Marketing analyst

33 avenue du Dr. Georges Levy
69693 Venissieux Cedex
France
simonin@flamel.com